Leerink Swann Reiterates Outperform Rating for ProQR Therapeutics NV (PRQR)
ProQR Therapeutics NV (NASDAQ:PRQR)‘s stock had its “outperform” rating restated by analysts at Leerink Swann in a research note issued on Friday.
A number of other brokerages have also issued reports on PRQR. Janney Montgomery Scott initiated coverage on ProQR Therapeutics NV in a report on Wednesday, September 28th. They issued a “neutral” rating and a $7.00 price objective for the company. Zacks Investment Research raised ProQR Therapeutics NV from a “sell” rating to a “hold” rating in a report on Saturday, September 17th. JMP Securities reissued a “buy” rating on shares of ProQR Therapeutics NV in a report on Tuesday, September 6th. Finally, Chardan Capital initiated coverage on ProQR Therapeutics NV in a report on Monday, June 20th. They issued a “neutral” rating and a $4.50 price objective for the company. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $14.15.
ProQR Therapeutics NV (NASDAQ:PRQR) traded up 7.0810% during trading on Friday, hitting $6.8746. The stock had a trading volume of 73,118 shares. The stock’s market cap is $160.49 million. The firm’s 50-day moving average price is $6.40 and its 200-day moving average price is $5.39. ProQR Therapeutics NV has a 1-year low of $3.48 and a 1-year high of $16.23.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/14/leerink-swann-reiterates-outperform-rating-for-proqr-therapeutics-nv-prqr.html
ProQR Therapeutics NV (NASDAQ:PRQR) last issued its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.00. On average, equities research analysts predict that ProQR Therapeutics NV will post ($2.09) earnings per share for the current fiscal year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Redmile Group LLC increased its stake in ProQR Therapeutics NV (NASDAQ:PRQR) by 5.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 581,638 shares of the biopharmaceutical company’s stock after buying an additional 28,925 shares during the period. Redmile Group LLC owned 2.49% of ProQR Therapeutics NV worth $2,815,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 39.21% of the company’s stock.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.